VBLT
$2.59
Vascular Biogen. Ord
$.03
1.17%
VBLT
Earnings Whisper ®
N/A
2nd Quarter June 2021
Consensus:  ($0.10)
Revenue:  $0.30 Mil
Tuesday
Aug 10
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VBLT reports earnings?
Beat
Meet
Miss

Where is VBLT's stock price going from here?
Up
Flat
Down
Stock chart of VBLT
Analysts
Summary of analysts' recommendations for VBLT
Score
Grade
Pivots
Resistance
$2.74
$2.67
$2.63

$2.57

Support
$2.53
$2.46
$2.42
Tweet
Growth
Description
Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.
Peers
InterCeptBioMarin PharmaceuticalVertex PharmaceuticalsZoetisUltragenyx PharmaceuticalRegeneron PharmaceuticalsBristol-Myers SquibbPfizerEli LillyMerck & Co.